A case of hyperinsulinemia of undetermined origin, successfully treated with long-acting octreotide

Endocrine Journal

Volumn 52, Issue 5, 2005, Pages 511-517

  Kondo, Tatsuya ^a   Tomita, Saori ^a   Adachi, Hironori ^a   Motoshima, Hiroyuki ^a   Taketa, Kayo ^a   Matsuyoshi, Akiko ^a   Tokunaga, Hiroshi ^a   Miyamura, Nobuhiro ^a   Araki, Eiichi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Hyperinsulinemia; Octreotide

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; IMMUNOREACTIVE INSULIN; INSULIN ANTIBODY; LONG ACTING DRUG; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

AGED; ARTICLE; CASE REPORT; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; IMAGING SYSTEM; INSULINOMA; LONG TERM CARE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS RESECTION; RECURRENT DISEASE; TREATMENT OUTCOME; TREATMENT REFUSAL; TUMOR LOCALIZATION;

AGED; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERINSULINISM; INSULIN; OCTREOTIDE;

EID: 27744486251     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.52.511     Document Type: Article

References (21)

1. Anlauf M, Wieben D, Perren A, Sipos B, Komminoth P, Raffel A, Kruse ML, Fottner C, Knoefel WT, Monig H, Heitz PU, Kloppel G (2005) Persistent hyperinsulinemic hypoglycemia in 15 adults with diffuse nesidioblastosis: diagnostic criteria, incidence, and characterization of beta-cell changes. Am J Surg Pathol 29: 524-533.
2. Doi R, Komoto I, Nakamura Y, Kawamura J, Fujimoto K, Wada M, Saga T, Imamura M (2004) Pancreatic endocrine tumor in Japan. Pancreas 28: 247-252.
3. Mittendorf EA, Liu YC, McHenry CR (2005) Giant insulinoma: case report and review of the literature. J Clin Endocrinol Metab 90: 575-580.
4. Battershill PE, Clissold SP (1989) Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 38: 658-702.
5. Gill GV, Rauf O, MacFarlane IA (1997) Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J 73: 640-641.
6. Takeda H, Watanabe K, Suzuki D, Miyano R, Tanaka K, Machimura H, Yagame M, Inoue W, Kaneshige H, Sakai H (1991) A case of insulin-secreting tumor successfully treated with diazoxide. Tokai J Exp Clin Med 16: 73-76.
7. Blum I, Rusecki Y, Doron M, Lahav M, Laron Z, Atsmon A (1983) Evidence for a therapeutic effect of dl-propranolol in benign and malignant insulinoma: report of three cases. J Endocrinol Invest 6: 41-45.
8. Eastman RC, Come SE, Strewler GJ, Gorden P, Kahn CR (1977) Adriamycin therapy for advanced insulinoma. J Clin Endocrinol Metab 44: 142-148.
9. Cohen MS, Bower RH, Fidler SM, Johnsonbaugh RE, Sode J (1973) Inhibition of insulin release by diphenylhydantoin and diazoxide in a patient with benign insulinoma. Lancet 1: 40-41.
10. Siegel EG, Janjic D, Wollheim CB (1982) Phenytoin inhibition of insulin release. Studies on the involvement of Ca2+ fluxes in rat pancreatic islets. Diabetes 31: 265-269.
11. Craig CE, Gallen IW (2002) Possible functional regression of insulinoma with prolonged octreotide. Postgrad Med J 78: 623-624.
12. Arnold R, Simon B, Wied M (2000) Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 62 (Suppl 1): 84-91.
13. Tanaka Y, Funahashi H, Imai T, Naruse T, Suzumura K, Oda Y (2000) The effectiveness of administering a minimal dose of octreotide long-term prior to surgery for insulinoma: report of a case. Surg Today 30: 541-543.
14. Barrons RW (1997) Octreotide in hyperinsulinism. Ann Pharmacother 31: 239-241.
15. Glaser B, Rosler A, Halperin Y (1990) Chronic treatment of a benign insulinoma using the long-acting somatostatin analogue SMS 201-995. Isr J Med Sci 26: 16-19.
16. Oda Y, Tanaka Y, Naruse T, Sasanabe R, Tsubamoto M, Funahashi H (2002) Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors. Surg Today 32: 690-694.
17. Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM, Bell GI, Schally AV, Vaysse N, Susini C (1995) Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 92: 1580-1584.
18. Teijeiro R, Rios R, Costoya JA, Castro R, Bello JL, Devesa J, Arce VM (2002) Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cell Physiol Biochem 12: 31-38.
19. Service FJ (1995) Hypoglycemic disorders. N Engl J Med 332: 1144-1152.
20. Kageyama K, Moriyama T, Hizuka N, Sakihara S, Takayasu S, Tamasawa N, Suda T (2003) Hypoglycemia associated with big insulin-like growth factor II produced during development of malignant fibrous histiocytoma. Endocr J 50: 753-758.
21. Jabri AL, Bayard C (2004) Nesidioblastosis associated with hyperinsulinemic hypoglycemia in adults: review of the literature. Eur J Intern Med 15: 407-410.